Recruiting

Plasma Exosome RNA

Sponsor:

Xijing Hospital

Code:

NCT07492927

Conditions

Clinically Significant Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Conditions

Clinically Significant Prostate Cancer

Study ID

NCT07492927

Start date

Mar 12, 2021

Status verified date

Mar, 2026

Completion date

Jun 30, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Blood prostate-specific antigen PSA>4ng/dl;
2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
3. The patient is willing to undergo prostate biopsy.

Exclusion Criteria:

1. Previous diagnosis of prostate cancer through prostate biopsy;
2. History of other malignant tumors in the past two years;
3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment

Study Design

Enrollment

1700 participants

Anticipated

Interventions and Outcome Measures

Arms

Study Cohort

The experimental arm receiving diagnosis from serum RNA combination

Primary outcome measure

  • The diagnostic efficacy of plasma exo-RNA panel alone in diagnosing csPCa [ Time Frame: The time of prostate biopsy ]

Central Contacts and Locations

Central contacts

Locations

Northwestern Memorial Hospital

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Principal Investigator:

Qiang Zhang, MD.

More Information

Sponsor

Xijing Hospital

Last update posted

Mar 25, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Xijing Hospital on 2026-03-25.